Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil

Ron Ram; Corina Herscovici; Dikla Dahan; Moshe Israeli; Juliet Dreyer; Anat Peck; Ofer Shpilberg; Moshe Yeshurun

doi:10.1016/j.leukres.2014.05.020

Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil

Ron Ram^*, Corina Herscovici, Dikla Dahan, Moshe Israeli, Juliet Dreyer, Anat Peck, Ofer Shpilberg, Moshe Yeshurun

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.

Original language	English
Pages (from-to)	913-917
Number of pages	5
Journal	Leukemia Research
Volume	38
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2014.05.020
State	Published - Aug 2014

Keywords

GVHD
Hematopoietic cell transplantation
MMF
Methotrexate

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2014.05.020

Cite this

@article{ee346ad756cb41d2a8577693ffac862b,

title = "Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil",

abstract = "We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.",

keywords = "GVHD, Hematopoietic cell transplantation, MMF, Methotrexate",

author = "Ron Ram and Corina Herscovici and Dikla Dahan and Moshe Israeli and Juliet Dreyer and Anat Peck and Ofer Shpilberg and Moshe Yeshurun",

year = "2014",

month = aug,

doi = "10.1016/j.leukres.2014.05.020",

language = "אנגלית",

volume = "38",

pages = "913--917",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "8",

}

TY - JOUR

T1 - Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil

AU - Ram, Ron

AU - Herscovici, Corina

AU - Dahan, Dikla

AU - Israeli, Moshe

AU - Dreyer, Juliet

AU - Peck, Anat

AU - Shpilberg, Ofer

AU - Yeshurun, Moshe

PY - 2014/8

Y1 - 2014/8

N2 - We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.

AB - We hypothesized that in patients with early post allogeneic transplantation toxicities, the omission of the 3rd dose of methotrexate with concomitant starting of MMF would favorably affect complications. We found a higher incidence of grade 2-4 acute GVHD in patients given two doses methotrexate and MMF (n=31) compared to those given three courses of methotrexate (n=70) (p=004), while grade 3-4 was similar. Other transplantation outcomes, including overall regimen-related-toxicity, were comparable. We conclude that tailoring the GVHD prophylaxis regimen may decrease the early post transplantation complications, however this come at the extent of a higher incidence of non-severe acute GVHD.

KW - GVHD

KW - Hematopoietic cell transplantation

KW - MMF

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=84904559978&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.05.020

DO - 10.1016/j.leukres.2014.05.020

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 24939215

AN - SCOPUS:84904559978

SN - 0145-2126

VL - 38

SP - 913

EP - 917

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this